These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28881737)

  • 1. Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice.
    Kwegyir-Afful AK; Murigi FN; Purushottamachar P; Ramamurthy VP; Martin MS; Njar VCO
    Oncotarget; 2017 Aug; 8(32):52381-52402. PubMed ID: 28881737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galeterone and VNPT55 disrupt Mnk-eIF4E to inhibit prostate cancer cell migration and invasion.
    Kwegyir-Afful AK; Bruno RD; Purushottamachar P; Murigi FN; Njar VC
    FEBS J; 2016 Nov; 283(21):3898-3918. PubMed ID: 27618366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo.
    Kwegyir-Afful AK; Ramalingam S; Ramamurthy VP; Purushottamachar P; Murigi FN; Vasaitis TS; Huang W; Kane MA; Zhang Y; Ambulos N; Tiwari S; Srivastava P; Nnane IP; Hussain A; Qiu Y; Weber DJ; Njar VCO
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling.
    Kuo SH; Yang SH; Wei MF; Lee HW; Tien YW; Cheng AL; Yeh KH
    Cancer Cell Int; 2021 Aug; 21(1):436. PubMed ID: 34412631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin.
    Xu Y; Liao S; Wang L; Wang Y; Wei W; Su K; Tu Y; Zhu S
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):85-93. PubMed ID: 33159561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aronia Berry Extract Modulates MYD88/NF-kB/P-Glycoprotein Axis to Overcome Gemcitabine Resistance in Pancreatic Cancer.
    Li Y; Xu C; Han H; Pascual-Sabater S; Fillat C; Goel A
    Pharmaceuticals (Basel); 2024 Jul; 17(7):. PubMed ID: 39065761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Integrin Subunit Alpha 2 (ITGA2) and Role of Mechanical Cues in Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma (PDAC).
    Gregori A; Bergonzini C; Capula M; Mantini G; Khojasteh-Leylakoohi F; Comandatore A; Khalili-Tanha G; Khooei A; Morelli L; Avan A; Danen EH; Schmidt T; Giovannetti E
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma.
    Qiu Z; Chu Y; Xu B; Wang Q; Jiang M; Li X; Wang G; Yu P; Liu G; Wang H; Kang H; Liu J; Zhang Y; Jin JP; Wu K; Liang J
    Oncotarget; 2017 Aug; 8(34):56428-56442. PubMed ID: 28915602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenascin-C induces resistance to apoptosis in pancreatic cancer cell through activation of ERK/NF-κB pathway.
    Shi M; He X; Wei W; Wang J; Zhang T; Shen X
    Apoptosis; 2015 Jun; 20(6):843-57. PubMed ID: 25690319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy.
    Laschanzky RS; Humphrey LE; Ma J; Smith LM; Enke TJ; Shukla SK; Dasgupta A; Singh PK; Howell GM; Brattain MG; Ly QP; Black AR; Black JD
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLE2 is associated with favorable prognosis and regulates cell growth and gemcitabine sensitivity in pancreatic cancer.
    Hu S; Chen Z; Gu J; Tan L; Zhang M; Lin W
    Ann Transl Med; 2020 Aug; 8(16):1017. PubMed ID: 32953817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2.
    Yao M; Hong Y; Liu Y; Chen W; Wang W
    Exp Ther Med; 2017 Sep; 14(3):2101-2107. PubMed ID: 28962130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing cytotoxic agent activity in experimental pancreatic cancer through EMAP II combination therapy.
    Awasthi N; Schwarz MA; Schwarz RE
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):571-82. PubMed ID: 21110024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
    Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
    Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
    Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
    Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S100 calcium-binding protein A6 promotes epithelial-mesenchymal transition through β-catenin in pancreatic cancer cell line.
    Chen X; Liu X; Lang H; Zhang S; Luo Y; Zhang J
    PLoS One; 2015; 10(3):e0121319. PubMed ID: 25799022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer.
    Ko S; Jung KH; Yoon YC; Han BS; Park MS; Lee YJ; Kim SE; Cho YJ; Lee P; Lim JH; Ryu JK; Kim K; Kim TY; Hong S; Lee SH; Hong SS
    Am J Cancer Res; 2022; 12(9):4326-4342. PubMed ID: 36225647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation.
    Wei WT; Chen H; Ni ZL; Liu HB; Tong HF; Fan L; Liu A; Qiu MX; Liu DL; Guo HC; Wang ZH; Lin SZ
    Int J Oncol; 2011 Dec; 39(6):1381-90. PubMed ID: 21805032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of SOX18 correlates with accelerated cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.
    Wang Y; Guo H; Zhang D; Yu X; Leng X; Li S; Zhu W
    Biochem Biophys Res Commun; 2016 Oct; 479(3):510-516. PubMed ID: 27663663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.